GENEVA/LONDON, Feb 3 (Reuters) - India’s Serum Institute will supply 1.1 billion doses of COVID-19 vaccines developed by AstraZeneca and Novavax to the COVAX vaccine scheme as part of a new long-term deal, head of the U.N. Children’s Fund said on Wednesday.
UNICEF chief Henrietta Fore said the shots would be delivered over a number of years at the cost of about $3 per dose for low- and middle-income countries.
They would be produced by Serum under a technology transfer agreement, she said in a briefing.
The COVAX facility is co-led by GAVI, the World Health Organization, the Coalition for Epidemic Preparedness Innovations and UNICEF. (Reporting by Stephanie Nebahay in Geneva and Kate Kelland in London; Writing by Josephine Mason; Editing by Toby Chopra)